Back
46· Steady
Markets2h 26m ago
UBS and Franklin Templeton stated this month that healthcare stocks are set to stage a turnaround and outperform the market.
Archive Window: 7 Days Left
global
Who
UBS, Franklin Templeton, Ulrike Hoffmann-Burchardi
What
UBS and Franklin Templeton stated this month that healthcare stocks are set to stage a turnaround and outperform the market.
When
Tue, 16 Jun 2026 09:40:02 GMT · 2h 26m ago
Where
global ·
Why
UBS cited GLP-1 weight-loss drugs as a huge growth driver, AI helping firms discover new drugs faster, and an aging global population creating inelastic demand for treatment; Franklin Templeton also highlighted AI, strong demand, and historically cheap stock valuations.
The Frontline Impact
How this affects you
UBS projects GLP-1 drugs could lead to a global market exceeding USD 100bn in revenues by 2030, suggesting significant growth for pharmaceutical stocks and the broader healthcare sector.
Story chain
3 events in this thread- Markets2h 26m agoUBS and Franklin Templeton indicate that healthcare stocks are poised for a turnaround, citing reasons like GLP-1 weight-loss drugs, AI in drug discovery, and an aging global population.Open article
- Currently Reading2h 26m agoUBS and Franklin Templeton stated this month that healthcare stocks are set to stage a turnaround and outperform the market.
- Markets2h 26m agoInvestment firms UBS and Franklin Templeton project healthcare stocks are set for a turnaround, citing factors like GLP-1 weight-loss drugs, AI in drug discovery, and an aging global population.Open article